Abuse-Deterrent Formulations Exempt From Medicaid Rebates Under Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Comprehensive opioid addiction legislation is considered by House-Senate conference committee on July 6.
You may also be interested in...
Abuse-Deterrent Exemption From Medicaid Rebates Hinges On FDA Standards
Opioid formulations with abuse-deterrent properties will be exempt from Medicaid price-inflation rebates if they meet FDA standards, Centers for Medicare and Medicaid Services says in guidance to manufacturers.
Medicare Part D Plans To Control Opioid Access With ‘Lock In’ Program
Addiction prevention legislation empowers Medicare drug plans to restrict prescriber, pharmacy access to opioids for ‘at risk’ beneficiaries.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.